Drugs for the acute treatment of migraine in children and adolescents

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Richer, Lawrence ^a   Billinghurst, Lori ^b   Linsdell, Meghan A ^a   Russell, Kelly ^c   Vandermeer, Ben ^a   Crumley, Ellen T ^d   Durec, Tamara ^e   Klassen, Terry P ^f   Hartling, Lisa ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d HealthInfo and Searching Practice Inc   (Canada)

^e Aberhart Centre   (Canada)

^f MANITOBA INSTITUTE OF CHILD HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; DIHYDROERGOTAMINE; ELETRIPTAN; IBUPROFEN; NAPROXEN PLUS SUMATRIPTAN; NARATRIPTAN; PARACETAMOL; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN; ANALGESIC AGENT; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ADOLESCENT DISEASE; ATTRIBUTABLE RISK; CHILDHOOD DISEASE; CROSSOVER PROCEDURE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY CARE; HUMAN; META ANALYSIS; MIGRAINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADOLESCENT; CHILD; MIGRAINE DISORDERS; TIME FACTOR;

ACETAMINOPHEN; ADOLESCENT; ANALGESICS, NON-NARCOTIC; CHILD; DIHYDROERGOTAMINE; HUMANS; IBUPROFEN; MIGRAINE DISORDERS; SEROTONIN RECEPTOR AGONISTS; TIME FACTORS; TRYPTAMINES;

EID: 84963735042     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005220.pub2     Document Type: Review

References (80)

1. Ahonen K, Hämäläinen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology 2004;62(6):883-7. [DOI: 10.1212/01.WNL.0000115105.05966.A7]
2. Ahonen K, Hämäläinen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006;67(7):1135-40. [DOI: 10.1212/01.wnl.0000238179.79888.44]
3. Callenbach PM, Pels LP, Mulder PG, Linssen WH, Gooskens RH, Van der Zwan JL, et al. Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children. European Journal of Paediatric Neurology 2007;11(6):325-30. [DOI: 10.1016/j.ejpn.2007.02.010]
4. SUM30042 A multi-centre, randomised, double-blind, placebo-controlled, cross-over study to investigate the efficacy, safety and tolerability of sumatriptan nasal spray (10mg or 20mg) in the treatment of migraine in patients aged 12-17. http://www.gsk-clinicalstudyregister.com/study/SUM30042#rs (accessed 24 June 2015).
5. Derosier FJ, Lewis D, Hershey AD, Winner PK, Pearlman E, Rothner AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics 2012;129(6):e1411-20. [DOI: 10.1542/peds.2011-2455]
6. Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]
7. Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia 2014;34(5):365-75. [DOI: 10.1177/0333102413510213]
8. SUM111035 A randomized, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral sumatriptan for the acute treatment of migraine in children and adolescents. http://www.gsk-clinicalstudyregister.com/study/111035#ps (accessed 24 June 2015).
9. Hämäläinen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]
10. Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?. Neurology 1997;48(4):1100-3. [PUBMED: 9109909]
11. Hämäläinen M, Hoppu K, Santavuori PR. Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatric Neurology 1997;16(2):114-7. [DOI: 10.1016/S0887-8994(96)00289-5]
12. Hämäläinen M, Jones M, Loftus J, Saiers J. Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. International Journal of Clinical Practice 2002;56(9):704-9. [PUBMED: 12469987]
13. SUM30009 A single centre, placebo-controlled, double blind, randomised cross-over, single attack study evaluating the efficacy and tolerability of sumatriptan nasal spray 10 mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura. http://www.gsk-clinicalstudyregister.com/study/SUM30009#rs (accessed 24 June 2015).
14. Ho TW, Pearlman E, Lewis D, Hämäläinen M, Connor K, Michelson D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Headache 2012;32(10):750-65. [DOI: 10.1177/0333102412451358]
15. Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S, et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache 2002;42(8):780-6. [DOI: 10.1046/j.1526-4610.2002.02180.x]
16. Lewis DW, Winner P, Hershey AD, Waslewski WW, Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics 2007;120(2):390-6. [DOI: 10.1542/peds.2007-0085]
17. Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache 2008;48(9):1326-36. [DOI: 10.1111/j.1526-4610.2008.01138.x]
18. NCT01211145 Zomig - treatment of acute migraine headache in adolescents (TEENZ). clinicaltrials.gov/ct2/show/NCT01211145 (accessed 24 June 2015).
19. Rothner A, Edwards K, Kerr L, DeBussey S, Asgharnejad M. Efficacy and safety of naratriptan tablets in adolescent migraine. Journal of Neurological Sciences 1997;150(Suppl 1):S106.
20. S2WA3012 A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population. http://www.gsk-clinicalstudyregister.com/study/S2WA3012#rs (accessed 24 June 2015).
21. Rothner D, Asgharnejad M. Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology 1999;6(Suppl 3):106.
22. SUMB2003 A double-blind, randomised, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg) in the acute treatment of migraine in adolescents. http://www.gsk-clinicalstudyregister.com/study/SUMB2003#rs (accessed 24 June 2015).
23. Rothner D, Asgharnejad M. Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology 1999;6(Suppl 3):106.
24. Rother D, Asgharnejad M. Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology 1999;6(Suppl 3):106. [GSK ID: S2CT40]
25. Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache 2006;46(1):101-9. [DOI: 10.1111/j.1526-4610.2006.00313.x]
26. Ueberall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology 1999;52(7):1507-10. [PUBMED: 10227648]
27. Visser WH, Winner P, Strohmaier K, Klipfel M, Peng Y, McCarroll K, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache 2004;44:891-9. [DOI: 10.1111/j.1526-4610.2004.04171.x]
28. Winner P, Prensky A, Linder S, DeBussey S, Asgharnejad M. Adolescent migraine: efficacy and safety of sumatriptan tablets. Journal of the Neurological Sciences 1997;150(Suppl 1):S172. [DOI: 10.1016/S0022-510X(97)85694-8]
29. Winner P, Rothner AD, Saper J, Nett R, Asgharnejad M, Laurenza A, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000;106(5):989-97. [PUBMED: 11061765]
30. Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 2002;42(1):49-55. [DOI: 10.1046/j.1526-4610.2002.02013.x]
31. SUM30045 A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (5mg And 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 years of age). http://www.gsk-clinicalstudyregister.com/study/SUM30045#rs (accessed 24 June 2015).
32. Winner P, Rothner AD, Wooten JD, Webster C, Ames M. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache 2006;46(2):212-22. [DOI: 10.1111/j.1526-4610.2006.00339.x]
33. Winner P, Rothner D, Webster CJ, Ames MH, Kori SH. Randomized, double-blind, placebo- controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology 2004;62(7 Suppl 5):A182.
34. Pitman V. Efficacy, safety and tolerability of oral eletriptan (40 mg) for the treatment of migraine in adolescents (12-17 years). Headache 2000;40(5):424-5.
35. Winner P, Liner SL, Lipton RB, Almas M, Parsons B, Pitman V. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache 2007;47(4):511-8. [DOI: 10.1111/j.1526-4610.2007.00755.x]
36. Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraines: a randomized, double-blind trial of prochlorperazine versus ketorolac. Annals of Emergency Medicine 2004;43(2):256-62. [DOI: 10.1016/S0196-0644(03)00716-9]
37. TM M) in the treatment of migraine. Headache 2011;51(7):1078-86. [DOI: 10.1111/j.1526-4610.2011.01910.x]
38. Gertsch EA, Loharuka S, Wolter-Warmerdam KG, Tong S, Kedia S. Intravenous magnesium as abortive treatment for headaches in children. Annals of Neurology 2011;70(S15):S167. [DOI: 10.1002/ana.22563]
39. NCT00355394 Treatment of acute migraine headache in children. clinicaltrials.gov/show/NCT00355394 (accessed 3 February 2016).
40. Soriani S, Battistella PA, Naccarella C, Tozzi E, Fiumana E, Fanaro S. Nimesulide and acetaminophen for the treatment of juvenile migraine: a study for comparison of efficacy, safety, and tolerability. Headache Quarterly 2001;12:233-6.
41. SUM40090 The use of oral sumatriptan on compassionate grounds for the acute treatment of migraine in adolescent patients (ages 12 to 17). http://www.gsk-clinicalstudyregister.com/study/SUM40090#rs. GlaxoSmithKline, (accessed 24 June 2015).
42. Trautmann E, Kroner-Herwig B. A randomized controlled trial of Internet-based self-help training for recurrent headache in childhood and adolescence. Behaviour Research & Therapy 2010;48(1):28-37. [DOI: 10.1016/j.brat.2009.09.004]
43. TM as early intervention for migraine in adolescents. Journal of Pediatric Neurology 2011;9(2):169-75. [DOI: 10.3233/JPN-2011-0471]
44. NCT01016678 Treximet Early Intervention Adolescent Migraine (TEAM). clinicaltrials.gov/ct2/show/NCT01016678 (accessed 24 June 2015).
45. Winner P, Linder S, Hershey AD. Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescents. Headache 2015;55:519-28. [DOI: 10.1111/head.12555]
46. Bille B. A 40-year follow-up of school children with migraine. Cephalalgia 1997;17(4):488-91; discussion 487. [DOI: 10.1046/j.1468-2982.1997.1704488.x]
47. Bonfert M, Straube A, Schroeder AS, Reilich P, Ebinger F, Heinen F. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics 2013;44(1):3-19. [DOI: 10.1055/s-0032-1330856]
48. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. II: binary outcomes. Statistics in Medicine 2002;21(15):2145-59. [DOI: 10.1002/sim.1206]
49. Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics 2005;116(2):e295-302. [DOI: 10.1542/peds.2004-2742]
50. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20(6):554-60. [DOI: 10.1046/j.1468-2982.2000.00082.x]
51. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629]
52. Eiland LS, Hunt MO. The use of triptans for pediatric migraines. Paediatric Drugs 2010;12(6):379-89. [DOI: 10.2165/11532860-000000000-00000]
53. Goadsby PJ. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia 2008;28(Suppl 2):36-41. [DOI: 10.1111/j.1468-2982.2008.01689.x]
54. McMaster University (developed by Evidence Prime, Inc.). GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.), 2015.
55. Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57. [DOI: 10.1002/sim.2380]
56. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [DOI: 10.1002/sim.1186]
57. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org. The Cochrane Collaboration.
58. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24(1 Suppl):1-160. [DOI: 10.1111/j.1468-2982.2003.00823.x]
59. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629-808. [DOI: 10.1177/0333102413485658]
60. International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8(Suppl 7):1-96.
61. Lathyris DN, Trikalinos TA, Ioannidis JP. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. International Journal of Epidemiology 2007;36(2):422-30. [DOI: 10.1093/ije/dym001]
62. Levy D, Zhang X-C, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: inhibition by naproxen. European Journal of Neuroscience 2008;27(4):917-22. [DOI: 10.1111/j.1460-9568.2008.06068.x]
63. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004;63(12):2215-24. [DOI: 10.1212/01.WNL.0000147332.41993.90]
64. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment?. Headache 2002;42(Suppl 1):3-9. [PUBMED: 11966858]
65. Major PW, Grubisa HSI, Thie NMR. Triptans for treatment of acute pediatric migraine: a systematic literature review. Pediatric Neurology 2003;29(5):425-9. [DOI: 10.1016/S0887-8994(03)00400-4]
66. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Annals of Pharmacotherapy 2010;44(3):489-506. [DOI: 10.1345/aph.1M332]
67. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics 2003;112(1 Pt 1):e1-5. [PUBMED: 12837897]
68. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in paediatric migraine: characterization of age-related effects using PedsQL 4.0. Cephalalgia 2004;24(2):120-7. [DOI: 10.1111/j.1468-2982.2004.00652.x]
69. Cochrane. Review Manager. Version 5.3. The Nordic Cochrane Centre, Copenhagen: Cochrane, 2014.
70. Silver S, Gano D, Gerretsen P. Acute treatment of paediatric migraine: a meta-analysis of efficacy. Journal of Paediatrics & Child Health 2008;44(1-2):3-9. [DOI: 10.1111/j.1440-1754.2007.01206.x]
71. StataCorp Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015.
72. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27(3):193-210. [DOI: 10.1111/j.1468-2982.2007.01288.x]
73. Sun H, Bastings E, Temeck J, Men A, Tandon V, Murphy D, et al. Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. JAMA Pediatrics 2013; Vol. 167, issue 3:243-9. [DOI: 10.1001/jamapediatrics.2013.872]
74. Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010;50(5):808-18. [DOI: 10.1111/j.1526-4610.2010.01635.x]
75. Tfelt-Hansen P, Pascual J, Ramadan N, Dahlof C, D'Amico D, Diener H-C, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32(1):6-38. [DOI: 10.1177/0333102411417901]
76. Toldo I, De Carlo D, Bolzonella B, Sartori S, Battistella PA. The pharmacological treatment of migraine in children and adolescents: an overview. Expert Review of Neurotherapeutics 2012;12(9):1133-42. [DOI: 10.1586/ern.12.104]
77. Vollono C, Vigevano F, Tarantino S, Valeriani M. Triptans other than sumatriptan in child and adolescent migraine: literature review. Expert Review of Neurotherapeutics 2011;11(3):395-401. [DOI: 10.1586/ern.10.147]
78. Winner P, Martinez W, Mate L, Bello L. Classification of pediatric migraine: proposed revisions to the IHS criteria. Headache 1995;35(7):407-10.
79. Wöber-Bingöl Ç. Pharmacological treatment of acute migraine in adolescents and children. Paediatric Drugs 2013;15(3):235-46. [DOI: 10.1007/s40272-013-0019-3]
80. Richer LP. Practice Variation in the Treatment of Children with Migraine in the Emergency Department [MSc Thesis]. Edmonton, AB: University of Alberta, 2009:132 pages.